Safety of drug-coated stents

Expert Opinion on Drug Safety

Volumn 7, Issue 5, 2008, Pages 597-606

  Biondi Zoccai, Giuseppe G L ^a   Moretti, Claudio ^a   Lotrionte, Marzia ^b   Sheiban, Imad ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Coronary artery disease; Drug eluting stent; Pecutaneous transluminal coronary angioplasty; Stent

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BIOLIMUS; CLOPIDOGREL; CYTOSTATIC AGENT; EVEROLIMUS; METAL; PACLITAXEL; POLYMER; RAPAMYCIN; TICLOPIDINE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTIFICIAL EMBOLISM; BIOCOMPATIBILITY; BIOSORPTION; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DISEASE; CYTOSTASIS; DRUG COATING; DRUG ELUTING STENT; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HEART ARRHYTHMIA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; IN-STENT RESTENOSIS; INFECTION; INFORMATION RETRIEVAL; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; MATERIAL COATING; MEDLINE; MORTALITY; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VASOSPASM; CORONARY ARTERY THROMBOSIS; PATIENT COMPLIANCE; RISK FACTOR; TIME;

CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; PACLITAXEL; PATIENT COMPLIANCE; RISK FACTORS; SIROLIMUS; TIME FACTORS;

EID: 54449100889     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.5.597     Document Type: Review

References (63)

1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301(2):61-8
2. Serruys PW, De Jaegere P, Kiemeneij F, et al. Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331(8):489-95
3. Fischman DL, Leon MB, Baim DS, et al. Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331(8):496-501
4. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91(6):1676-88
5. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006;151(6):1260-4
6. Biondi-Zoccai GG, Agostoni P, Sheiban I. Last nail in the coffin of late lumen loss? EuroInterv 2008;4:29-32
7. Grube E, Lansky A, Hauptmann KE, et al. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol 2004;44(7):1368-72
8. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 2004;44(7):1373-85
9. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346(23):1773-80
10. Colombo A, Drzewiecki J, BanningA, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108(7):788-94
11. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349(14):1315-23
12. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 3503:221-231
13. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiphtelet therapy. Lancet 2004;364(9444):1519-21
14. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007;49(6):734-9
15. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006;27(23):2784-814
16. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115(11):1440-55
17. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356(10):1009-19
18. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356(10):1030-9
19. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356(10):998-1008
20. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357(14):1393-402
21. Biondi-Zoccai G, Agostoni P, Moretti C, et al. Making sense of the recent meta-analytic confusion concerning the safety of drug-eluting stent. EuroInterv 2007;3:381-5
22. Stone GW, Ellis SG, Colombo A, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 2007;115(22):2842-7
23. Muni NI, Gross TP. Problems with drug-eluting coronary stents-the FDA perspective. N Engl J Med 2004;351(16):1593-5
24. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48(1):193-202
25. Togni M, Raber L, Cocchia R, et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 2007;120(2):212-20
26. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109(6):701-5
27. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47(1):175-81
28. Le MQ, Narins CR. Mycotic pseudoaneurysm of the left circumflex coronary artery: a fatal complication following drug-eluting stent implantation. Catheter Cardiovasc Interv 2007;69(4):508-12
29. Alfonso F, Moreno R, Vergas J. Fatal infection after rapamycin eluting coronary stent implantation. Heart 2005;91(6):e51
30. Tanabe K, Serruys PW, Degertekin M, et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation 2005;111(7):900-5
31. Ako J, Morino Y, Honda Y, et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol 2005;46(6):1002-5
32. Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 2006;113(3):414-9
33. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115(18):2426-34
34. Stabile E, Escolar E, Weigold G, et al. Marked malapposition and aneurysm formation after sirolimus-eluting coronary stent implantation. Circulation 2004;110(5):e47-8
35. Gupta RK, Sapra R, Kaul U. Early aneurysm formation after drug-eluting stent implantation: an unusual life-threatening complication. J Invasive Cardiol 2006;18(4):E140-2
36. Cosgrave J, Corbett SJ, Melzi G, et al. Late restenosis following sirolimus-eluting stent implantation. Am J Cardiol 2007;100(i):41-4
37. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002;106(10):1205-10
38. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294(10):1215-23
39. Kereiakes DJ, Wang H, Popma JJ, et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol 2006;48(1):21-31
40. Jang JS, Hong MK, Park DW, et al. Impact of periprocedural myonecrosis on clinical events after implantation of drug-eluting stents. Int J Cardiol 2008; In press
41. Kim SW, Mintz GS, Ohlmann P, et al. Frequency and severity of plaque prolapse within Cypher and Taxus stents as determined by sequential intravascular ultrasound analysis. Am J Cardiol 2006;98(9):1206-11
42. Futamatsu H, Sabate M, Angiolillo DJ, et al. Characterization of plaque prolapse after drug-eluting stent implantation in diabetic patients: a three-dimensional volumetric intravascular ultrasound outcome study. J Am Coll Cardiol 2006;48(6):1139-45
43. Chu CS, Lee ST, Lee KT, et al. Successful retrieval of dislodged paclitaxel-eluting stent with a nitinol loop snare: a case report. Kaohsiung J Med Sci 2005;21(12):566-70
44. Roffi M, Luscher TF, Sutsch G, et al. Failure to retrieve undeployed paclitaxel-eluting coronary stents. Am J Cardiol 2006;97(4):502-5
45. Brilakis ES, Best PJ, Elesber AA, et al. Incidence, retrieval methods, and outcomes of stent loss during percutaneous coronary intervention: a large single-center experience. Catheter Cardiovasc Interv 2005;66(3):333-40
46. Steinberg DH, Satler LF, Pichard AD. Snare extraction of a fractured coronary stent in a saphenous vein graft. Catheter Cardiovasc Interv 2007;70(2):241-3
47. Chung WS, Park CS, Seung KB, et al. The incidence and clinical impact of stent strut fractures developed after drug-eluting stent implantation. Int J Cardiol 2008;125(3):325-31
48. Lee MS, Jurewitz D, Aragon J, et al. Stent fracture associated with drug-eluting stents: clinical characteristics and implications. Catheter Cardiovasc Interv 2007;69(3):387-94
49. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115(17):2344-51
50. Chieffo A, Bonizzoni E, Orlic D, et al. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 2004;109(22):2732-6
51. Biondi-Zoccai GG, Sangiorgi GM, Chieffo A, et al. Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era. Am J Cardiol 2005;95(12):1466-8
52. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45(6):947-53
53. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293(17):2126-30
54. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119(12):1056-61
55. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356(10):989-97
56. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet 2008;371(9630):2134-43
57. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356(10):1020-9
58. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370(9591):937-48
59. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirulimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369(9562):667-78
60. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116(7):745-54
61. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297(2):159-68
62. Biondi-Zoccai GG, Lotrionte M, Abbate A, et al. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ 2006;332(7535):202-9
63. Hodgson JM, Stone GW, Lincoff AM, et al. Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force. Catheter Cardiovasc Interv 2007;69(3):327-33